Redhill Biopharma Stock Price Prediction
| RDHL Stock | USD 0.42 0.03 7.69% |
Oversold Vs Overbought
43
Oversold | Overbought |
Redhill Biopharma stock price prediction is an act of determining the future value of Redhill Biopharma shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Redhill Biopharma's future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Redhill Biopharma and does not consider all of the tangible or intangible factors available from Redhill Biopharma's fundamental data. We analyze noise-free headlines and recent hype associated with Redhill Biopharma, which may create opportunities for some arbitrage if properly timed.
Below are the key fundamental drivers impacting Redhill Biopharma's stock price prediction:Wall Street Target Price 760 | Quarterly Revenue Growth (0.96) |
It is a matter of debate whether stock price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of Redhill Biopharma based on different types of headlines from major news networks to social media. The Redhill stock price prediction module provides an analysis of price elasticity to changes in media outlook on Redhill Biopharma over a specific investment horizon. Using Redhill Biopharma hype-based prediction, you can estimate the value of Redhill Biopharma from the perspective of Redhill Biopharma response to recently generated media hype and the effects of current headlines on its competitors.
This module is based on analyzing investor sentiment around taking a position in Redhill Biopharma. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in Redhill Biopharma to buy its stock at a price that has no basis in reality. In that case, they are not buying Redhill because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Redhill Biopharma after-hype prediction price | USD 0.4 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Redhill |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Redhill Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Redhill Biopharma After-Hype Price Prediction Density Analysis
As far as predicting the price of Redhill Biopharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Redhill Biopharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Redhill Biopharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Redhill Biopharma Estimiated After-Hype Price Volatility
In the context of predicting Redhill Biopharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Redhill Biopharma's historical news coverage. Redhill Biopharma's after-hype downside and upside margins for the prediction period are 0.02 and 7.70, respectively. We have considered Redhill Biopharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Redhill Biopharma is moderately volatile at this time. Analysis and calculation of next after-hype price of Redhill Biopharma is based on 3 months time horizon.
Redhill Biopharma Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Redhill Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Redhill Biopharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Redhill Biopharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.97 | 7.30 | 0.02 | 0.64 | 10 Events / Month | 5 Events / Month | In about 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
0.42 | 0.40 | 4.76 |
|
Redhill Biopharma Hype Timeline
Redhill Biopharma is at this time traded for 0.42. The entity has historical hype elasticity of -0.02, and average elasticity to hype of competition of 0.64. Redhill is forecasted to decline in value after the next headline, with the price expected to drop to 0.4. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -4.76%, whereas the daily expected return is at this time at -0.97%. The volatility of related hype on Redhill Biopharma is about 1103.27%, with the expected price after the next announcement by competition of 1.06. The company had not issued any dividends in recent years. Redhill Biopharma had 1:40 split on the 23rd of March 2023. Given the investment horizon of 90 days the next forecasted press release will be in about 10 days. Check out Redhill Biopharma Basic Forecasting Models to cross-verify your projections.Redhill Biopharma Related Hype Analysis
Having access to credible news sources related to Redhill Biopharma's direct competition is more important than ever and may enhance your ability to predict Redhill Biopharma's future price movements. Getting to know how Redhill Biopharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Redhill Biopharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ALKS | Alkermes Plc | 0.36 | 9 per month | 0.00 | (0.09) | 2.79 | (4.24) | 21.89 | |
| IRWD | Ironwood Pharmaceuticals | 0.31 | 12 per month | 0.00 | (0.10) | 3.82 | (4.53) | 42.91 | |
| DCPH | Deciphera Pharmaceuticals LLC | (0.12) | 10 per month | 2.52 | (0.02) | 4.84 | (4.32) | 17.94 | |
| EGRX | Eagle Pharmaceuticals | (0.40) | 10 per month | 4.87 | 0.03 | 8.00 | (7.92) | 23.10 | |
| NBIX | Neurocrine Biosciences | 4.08 | 10 per month | 1.56 | (0.04) | 2.61 | (2.36) | 8.06 | |
| DVAX | Dynavax Technologies | (0.26) | 9 per month | 0.00 | (0.27) | 2.49 | (2.90) | 6.78 |
Redhill Biopharma Additional Predictive Modules
Most predictive techniques to examine Redhill price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Redhill using various technical indicators. When you analyze Redhill charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Redhill Biopharma Predictive Indicators
The successful prediction of Redhill Biopharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Redhill Biopharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Redhill Biopharma based on analysis of Redhill Biopharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Redhill Biopharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Redhill Biopharma's related companies. | 2021 | 2022 | 2023 | 2024 (projected) | Graham Number | 129.89 | 164.06 | 5.15 | 4.89 | Receivables Turnover | 2.64 | 1.75 | 1.98 | 2.06 |
Story Coverage note for Redhill Biopharma
The number of cover stories for Redhill Biopharma depends on current market conditions and Redhill Biopharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Redhill Biopharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Redhill Biopharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
View All Premium Stories
Redhill Biopharma Short Properties
Redhill Biopharma's future price predictability will typically decrease when Redhill Biopharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Redhill Biopharma often depends not only on the future outlook of the potential Redhill Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Redhill Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 6.5 M | |
| Cash And Short Term Investments | 6.4 M |
Check out Redhill Biopharma Basic Forecasting Models to cross-verify your projections. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.Note that the Redhill Biopharma information on this page should be used as a complementary analysis to other Redhill Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for Redhill Stock analysis
When running Redhill Biopharma's price analysis, check to measure Redhill Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Redhill Biopharma is operating at the current time. Most of Redhill Biopharma's value examination focuses on studying past and present price action to predict the probability of Redhill Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Redhill Biopharma's price. Additionally, you may evaluate how the addition of Redhill Biopharma to your portfolios can decrease your overall portfolio volatility.
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |
Is Redhill Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 4 | Revenue Per Share 1.008 | Quarterly Revenue Growth (0.96) | Return On Assets (0.16) | Return On Equity (8.84) |
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.